Wire · regulatory
FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 November 2026 · Fusion42 review
The FDA has approved Bayer's asundexian, the first oral factor XIa inhibitor, to reduce recurrent stroke risk in adults after noncardioembolic ischemic stroke or high-risk TIA, based on positive phase 3 trial results showing reduced ischemic stroke without significant major bleeding increase.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
You face a new treatment option approved for secondary stroke prevention that lowers recurrent strokes without raising major bleeding risks. Update your clinical and partner strategies to reflect this advance in oral anticoagulants.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics